Praxis Precision Medicines general counsel sells $4.8m in shares
Investing.com - Needham raised its price target on Azenta, Inc. (NASDAQ:AZTA) to $42.00 from $40.00 on Friday, while maintaining a Buy rating on the stock. This new target closely aligns with InvestingPro’s Fair Value assessment, suggesting the stock may be undervalued at its current price of $34.69, despite a 40% year-to-date decline.
The price target increase follows Azenta’s fourth-quarter fiscal 2025 results, which showed both revenue and EBITDA exceeding consensus expectations. InvestingPro data reveals Azenta holds more cash than debt on its balance sheet, with a healthy current ratio of 2.76, indicating strong short-term financial stability.
Management provided fiscal year 2026 revenue guidance that aligned with market consensus, while its EBITDA margin guidance came in above Street estimates.
Despite ongoing constraints in Azenta’s end-markets, the company expects to see benefits from initiatives implemented in fiscal year 2025, which should drive both growth and margins in the coming year.
Needham highlighted several potential catalysts, including a possible B Medical sale announcement before the end of calendar year 2025 and an upcoming Investor Day scheduled for December 10, 2025, which could positively impact the stock.
In other recent news, Azenta Inc. reported its fourth-quarter 2025 earnings, surpassing analysts’ expectations. The company achieved a non-GAAP earnings per share (EPS) of $0.21, compared to the forecasted $0.19, representing a 10.53% positive surprise. Additionally, Azenta’s revenue reached $159 million, exceeding the anticipated $156.46 million. These results indicate stronger-than-expected financial performance for the quarter. The earnings announcement reflects recent developments in the company’s financial landscape. The positive earnings surprise and revenue outperformance are significant highlights for investors.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.